Review
doi: 10.1089/cap.2007.0031.
Commentary by a child psychiatrist in industry on the assessment of drug safety
Affiliations
- PMID: 17630860
- DOI: 10.1089/cap.2007.0031
Item in Clipboard
Review
Commentary by a child psychiatrist in industry on the assessment of drug safety
J Child Adolesc Psychopharmacol.
2007 Jun.
No abstract available
Similar articles
-
Manufacturing uncertainty: adverse effects of drug development for women.Int J Law Psychiatry. 2003 Sep-Oct;26(5):515-32. doi: 10.1016/S0160-2527(03)00084-0. Int J Law Psychiatry. 2003. PMID: 14522223 No abstract available.
-
US lawmakers tackle safety reforms at the FDA.Lancet. 2007 Jun 16;369(9578):1989-90. doi: 10.1016/S0140-6736(07)60928-3. Lancet. 2007. PMID: 17577942 No abstract available.
-
Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.JAMA Intern Med. 2014 Oct;174(10):1704-5. doi: 10.1001/jamainternmed.2014.4854. JAMA Intern Med. 2014. PMID: 25127107 No abstract available.
-
Postmarketing surveillance and reporting of adverse drug events.S D J Med. 2004 Jan;57(1):13-4. S D J Med. 2004. PMID: 14964975 Review. No abstract available.
-
New approaches to drug safety: a pharmacovigilance tool kit.Nat Rev Drug Discov. 2009 Oct;8(10):779-82. doi: 10.1038/nrd3002. Epub 2009 Sep 18. Nat Rev Drug Discov. 2009. PMID: 19763106 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
